Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kuangli Bio-Tech Holdings CoTPE:6431 -1.76%66 Cyclically Adjusted PS Ratio is 2.91 as of Jul. 29, 2026, which is 11% above its 10-year median of 2.61. GuruFocus rates TPE:6431 with a GF Score™ of 66/100 and a GF Value™ of NT$11.62 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,449 Consumer Packaged Goods companies, Kuangli Bio-Tech Holdings Co ranks worse than 87.85% on this metric.
The historical rank and industry rank for Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
TPE:6431'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.39 Med: 2.61 Max: 5.19
Current: 3
During the past years, Kuangli Bio-Tech Holdings Co's highest Cyclically Adjusted PS Ratio was 5.19. The lowest was 1.39. And the median was 2.61.
TPE:6431's Cyclically Adjusted PS Ratio is ranked worse than 87.85% of 1449
companies
in the Consumer Packaged Goods industry
Industry Median: 0.76
vs TPE:6431: 3.00
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Kuangli Bio-Tech Holdings Co's adjusted revenue per share data for the three months ended in Dec. 2025 was NT$1.170. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$5.73 for the trailing ten years ended in Dec. 2025.
Shiller PE for Stocks: The True Measure of Stock Valuation
Kuangli Bio-Tech Holdings Co (TPE:6431) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Kuangli Bio-Tech Holdings Co Cyclically Adjusted PS Ratio Related Terms
Kuangli Bio-Tech Holdings Co Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kuangli Bio-Tech Holdings Co Cyclically Adjusted PS Ratio Chart
TPE:6431 vs PG, CL, KVUE: Cyclically Adjusted PS Ratio Comparison
For the Household & Personal Products subindustry, Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kuangli Bio-Tech Holdings Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio falls into.
Kuangli Bio-Tech Holdings Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 2.91 mean?
Kuangli Bio-Tech Holdings Co (TPE:6431) has a Cyclically Adjusted PS Ratio of 2.91 as of Jul. 29, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kuangli Bio-Tech Holdings Co and its competitors. This is 11% above median its historical median of 2.61. Over the past decade, Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio has ranged from 1.39 to 5.19. According to the industry distribution chart, Kuangli Bio-Tech Holdings Co ranks #1273 out of 1449 companies in the Consumer Packaged Goods industry, placing it in the top 87.9%.
Is Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio too high?
Kuangli Bio-Tech Holdings Co's current Cyclically Adjusted PS Ratio of 2.91 is 11% above median its 10-year median of 2.61. Over the past 10 years, this metric has ranged from a low of 1.39 to a high of 5.19. The Consumer Packaged Goods industry median Cyclically Adjusted PS Ratio is 0.76. Kuangli Bio-Tech Holdings Co's value of 2.91 is 282.9% above this industry median. Based on the distribution chart, Kuangli Bio-Tech Holdings Co ranks #1273 out of 1449 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Kuangli Bio-Tech Holdings Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Kuangli Bio-Tech Holdings Co ranks #1273 out of 1449 companies for Cyclically Adjusted PS Ratio. This places Kuangli Bio-Tech Holdings Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 0.76. Kuangli Bio-Tech Holdings Co's value of 2.91 is 282.9% above this benchmark. Historically, Kuangli Bio-Tech Holdings Co's own Cyclically Adjusted PS Ratio has ranged from 1.39 to 5.19 over the past decade. While the company's 10-year median is 2.61 vs. the industry median of 0.76, Kuangli Bio-Tech Holdings Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Consumer Packaged Goods company?
The median Cyclically Adjusted PS Ratio among Consumer Packaged Goods companies is 0.76, based on 1,449 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kuangli Bio-Tech Holdings Co's current Cyclically Adjusted PS Ratio of 2.91 is 282.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kuangli Bio-Tech Holdings Co and its competitors. For the Consumer Packaged Goods industry, the median Cyclically Adjusted PS Ratio is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kuangli Bio-Tech Holdings Co's current Cyclically Adjusted PS Ratio is 2.91, which is 11% above median its own 10-year median of 2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuangli Bio-Tech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co (TPE:6431) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$11.62, compared to a current price of NT$16.70 — trading 43.7% above its estimated fair value. The current Cyclically Adjusted PS Ratio is 2.91, which is 11% above median its 10-year median of 2.61 and 282.9% above the Consumer Packaged Goods industry median of 0.76. Kuangli Bio-Tech Holdings Co's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Kuangli Bio-Tech Holdings Co (TPE:6431), the current Cyclically Adjusted PS Ratio is 2.91 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kuangli Bio-Tech Holdings Co (TPE:6431) Overvalued in 2026?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co stock appears to be overvalued.
The current stock price of NT$16.70 is trading 43.7% above its estimated GF Value™ of NT$11.62.
GuruFocus considers Kuangli Bio-Tech Holdings Co to be Significantly Overvalued.
Key valuation signals for TPE:6431:
Cyclically Adjusted PS Ratio: 2.91 (11% above median its 10-year median of 2.61)
GF Value™: NT$11.62 vs. price of NT$16.70 (43.7% above fair value)
Industry Position: 282.9% above the Consumer Packaged Goods median (#1273 of 1449)
No single metric tells the full story. See the TPE:6431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kuangli Bio-Tech Holdings Co Ltd is mainly engaged in the manufacture and trading of various types of panels (LENS), such as mobile phone panels, digital camera windows, PDA panels, and instrument panels. The company is also engaged in the development, manufacturing and trading of cosmetics and skin care products and other related biotechnology products. It derives revenue from Health and Wellness products, and Cosmetics and skin care products, including Lotion, Facial masks, and Other pastes. The primary source of revenue for the company is sales of cosmetic products.
66GF Score
Get the complete analysis for TPE:6431
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6431 has been successfully added to your 
